Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDT501 in Insulin Resistant Subjects
NCT02444910Phase 2Completed
- Sponsor
- KinDex Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KDT-501 in insulin resistance (IR), metabolic syndrome, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), sponsored by KinDex Pharmaceuticals. Started Apr 2015; status: completed.
02
Drugs
KDT-501
03
Conditions
insulin resistance (IR)metabolic syndromeimpaired glucose tolerance (IGT)impaired fasting glucose (IFG)
Beyond the preview
Go deeper on NCT02444910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444910.